| RCL |
Report |
Adjusted EPS |
BEAT |
pred ~$4.08 vs. cons $4.02 |
MEDIUM |
| RCL |
Report |
Net revenue |
IN-LINE |
pred ~$3.91B vs. cons $3.893B |
MEDIUM |
| RCL |
Report |
CC net-yield growth |
BEAT |
pred ~+0.70% vs. cons +0.58% |
MEDIUM |
| RCL |
Guide |
Adjusted EPS (Q3 2026) |
UNCHANGED |
guide ~$6.34-$6.44 vs. cons $6.42 |
LOW |
| RCL |
Guide |
Adjusted EPS (FY 2026) |
UNCHANGED |
guide ~$17.10-$17.50 vs. cons $17.42 |
MEDIUM |
| RCL |
Guide |
Bookings / Mediterranean recovery (2H 2026) |
BETTER |
recovery commentary better than prior concern; consensus UNVERIFIED |
LOW |
| RCL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| RCL |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit Q4 cut should pull estimates lower |
LOW |